A PILOT STUDY OF NY-ESO PLUS CPG 7909 AND MONTANIDE IN PATIENTS WITH CANCER

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。为了产生比先前临床研究更强和更临床相关的NY-ESO-1免疫，将HLA-A2限制性NY-ESO-1b肽（SLLMWITQC;位置157-165）与Montanide伊萨（商标）51加CpG 7909混合，并通过皮下注射给予患有表达NY-ESO-1或拉格-1抗原的癌症的HLA-A2患者。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In an attempt to generate stronger and more clinically relevant NY-ESO-1 immunity than in previous clinical studies, the HLA-A2 restricted NY-ESO-1b peptide (SLLMWITQC; position 157-165) will be mixed with Montanide ISA(Trademark) 51 plus CpG 7909 and given by subcutaneous injection to HLA-A2 patients with cancer expressing the NY-ESO-1 or LAGE-1 antigen.